drugset
drugset / Trial / NCT00396422

Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis

NCT00396422 ↗

Phase 2 Completed 60 enrolled Alza Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis

Timeline

Start
2006-09
Primary completion
—
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RWJ-445380 Unknown 50 mg Oral
Subject RWJ-445380 Unknown 100 mg Oral
Subject RWJ-445380 Unknown 200 mg Oral
Subject RWJ-445380 Unknown 300 mg Oral

Indications

psoriasis